In groundbreaking move, FDA approves Myovant's relugolix as the first once-a-day pill for advanced prostate cancer

Myovant Sciences $MYOV won’t be getting coal in their stocking this Christmas.

The Swiss biotech, formerly part of the Vivek Ramaswamy family of Vants, won FDA approval of its relugolix drug on Friday afternoon for the treatment of advanced prostate cancer. It’s the first oral hormone therapy approved for the indication, regulators said, and the drug will be marketed as Orgovyx. PDUFA action had been scheduled for Dec. 20.